Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (Nasdaq: XOMA) is a biotechnology royalty aggregator that regularly reports on transactions, partner developments, and portfolio evolution. News about XOMA Royalty often centers on its acquisition of royalty and milestone interests in therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies, as well as on corporate events that affect its capital structure and governance.
Recent announcements highlight XOMA Royalty’s completion of acquisitions of companies such as HilleVax, LAVA Therapeutics, Mural Oncology, and Turnstone Biologics, which add partnered programs and associated economic interests to its portfolio. The company also issues updates on strategic royalty-sharing transactions, including amendments to its collaboration with Takeda related to mezagitamab and exposure to a basket of development-stage assets in Takeda’s externalized assets portfolio.
Investors following XOMA Royalty news will see regular disclosures on quarterly and year-to-date financial results, including royalty and milestone receipts from commercial assets like VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, and DSUVIA. The company’s releases also summarize key clinical and regulatory milestones reported by its partners, since these events can influence the timing and magnitude of potential royalty and milestone payments.
Additional news items cover preferred stock dividends on the company’s Series A and Series B Cumulative Perpetual Preferred Stock, at-the-market offerings of common and preferred securities, and leadership changes such as transitions in the Chief Financial Officer role. For investors and observers, the XOMA Royalty news feed provides a consolidated view of business development activity, partner pipeline progress, financing decisions, and governance updates that shape the company’s royalty and milestone portfolio over time.
Ligand (Nasdaq: LGND) will acquire XOMA Royalty (Nasdaq: XOMA) for $39.00 per share in cash, valuing XOMA Royalty at approximately $739 million and including one non-transferable CVR per share tied to potential litigation proceeds. The deal adds seven marketed products, >120 assets, and is expected to close in Q3 2026, be immediately accretive to Ligand adjusted EPS, and raise Ligand's 2026 guidance to $270M–$310M revenue and adjusted EPS $8.50–$9.50.
XOMA Royalty (Nasdaq: XOMA) declared quarterly cash dividends for its preferred securities on March 18, 2026. Series A (Nasdaq: XOMAP) will receive $0.53906 per share; Series B depositary shares (Nasdaq: XOMAO) will receive $0.52344 per depositary share.
Both dividends are payable on or about April 15, 2026 to holders of record at the close of business on April 2, 2026.
Summary not available.
XOMA Royalty (NASDAQ: XOMA) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. The company will host a live webcast on March 18, 2026 at 8:00 AM ET to discuss results and provide a business update.
According to the company, the webcast will be accessible on the Investors "News & Events" page and a replay will be available for 30 days after the live event.
XOMA Royalty (NASDAQ: XOMA) said members of its executive team will present at investor conferences in March 2026, including a fireside chat at the T.D. Cowen 46th Annual Health Care Conference on March 2 and at the Leerink 2026 Global Healthcare Conference on March 11.
Both presentations will include one-on-one investor meetings, and replays will be available on the company investor relations website and archived for 90 days after each event.
XOMA Royalty (NASDAQ: XOMA) announced it completed its tender offer and acquisition of Generation Bio (NASDAQ: GBIO). Generation Bio stockholders received $4.2913 per share in cash plus one non-tradeable contingent value right (CVR). Approximately 4,722,533 shares (~70%) were validly tendered. Following the tender, XRA 7 Corp. merged into Generation Bio, which became a wholly owned subsidiary of XOMA Royalty. Trading in Generation Bio common stock ceased on Nasdaq after market close on February 6, 2026, and the companies intend to delist and deregister those shares.
XOMA Royalty (Nasdaq: XOMA) announced on January 12, 2026 that Chief Financial Officer Thomas Burns will step down to pursue other opportunities after nearly two decades with the company. The board thanked Burns for his leadership during XOMA Royalty’s transition to a royalty aggregator and for building a strong financial foundation. The company appointed Jeffrey Trigilio as CFO; he previously served as CFO and COO at Obsidian Therapeutics and as CFO at Cullinan Therapeutics, and began his career at Alexion Pharmaceuticals. Management emphasized continued disciplined capital deployment, diligence, and deal structuring to grow the royalty portfolio and deliver value for shareholders.
XOMA Royalty (NASDAQ: XOMA) and Takeda amended their 2006 collaboration via a strategic royalty share transaction announced Dec 30, 2025. Takeda regains a majority of XOMA Royalty’s mezagitamab economics while XOMA Royalty will retain a low single-digit royalty on mezagitamab and up to $13.0 million in milestones (previously mid-single-digit royalty and $16.25 million in potential milestones).
In exchange, XOMA Royalty will receive payments (low to mid-single-digit royalties and milestones) tied to a basket of nine development-stage assets from Takeda’s externalized portfolio, including programs from Neurocrine, Mirum, Oak Hill Bio, Recursion, and others.
XOMA Royalty (Nasdaq: XOMA) declared quarterly cash dividends for its preferred shares on Dec 22, 2025. The Board authorized a dividend of $0.53906 per share for the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) and $0.52344 per depositary share for depositary shares representing 1/1000 of the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO).
Both preferred dividends are payable on or about Jan 15, 2026 to holders of record at the close of business on Jan 2, 2026.
XOMA Royalty (Nasdaq: XOMA) announced it has completed the acquisition of Mural Oncology (Nasdaq: MURA) by way of an Irish High Court sanctioned scheme of arrangement.
Mural shareholders received $2.035 cash per share as the consideration. The scheme was sanctioned by the Irish High Court on December 3, 2025 and became effective on December 5, 2025 upon delivery of the court order to the Irish Companies Registration Office.
Prior to trading on December 5, 2025, Mural shares will cease trading on Nasdaq and Mural intends to seek prompt delisting and deregistration under the Securities Exchange Act of 1934.